We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Transaction expands Boehringer Ingelheim’s R&D and clinical manufacturing capabilities with a site focused predominantly on ATMP-based cancer immunology treatments.